Beta-lactam and Beta-lactamase Inhibitors Market Analysis 2022-2028 with Industry Chain Structure, Competitive Landscape

Latest research report on “Beta-lactam and Beta-lactamase Inhibitors Market” now available at high quality database of ReportsnReports.com with market size, share, trends, competitive and statistical analysis. An exclusive data offered in this report is collected by research and industry experts team.

Get Free Sample Copy @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5611977

?-Lactams are the most widely used class of antibiotics. Since the discovery of benzylpenicillin in the 1920s, thousands of new penicillin derivatives and related ?-lactam classes of cephalosporins, cephamycins, monobactams, and carbapenems have been discovered. Each new class of b-lactam has been developed either to increase the spectrum of activity to include additional bacterial species or to address specific resistance mechanisms that have arisen in the targeted bacterial population. Resistance to ?-lactams is primarily because of bacterially produced ?-lactamase enzymes that hydrolyze the ?-lactam ring, thereby inactivating the drug. The newest effort to circumvent resistance is the development of novel broad-spectrum ?-lactamase inhibitors that work against many problematic ?-lactamases, including cephalosporinases and serine-based carbapenemases, which severely limit therapeutic options.
This report contains market size and forecasts of Beta-lactam and Beta-lactamase Inhibitors in global, including the following market information:
Global Beta-lactam and Beta-lactamase Inhibitors Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Beta-lactam and Beta-lactamase Inhibitors Market Sales, 2017-2022, 2023-2028, (M Units)
Global top five Beta-lactam and Beta-lactamase Inhibitors companies in 2021 (%)
The global Beta-lactam and Beta-lactamase Inhibitors market was valued at 29150 million in 2021 and is projected to reach US$ 33070 million by 2028, at a CAGR of 1.8% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Penicillins Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Beta-lactam and Beta-lactamase Inhibitors include Pfizer, Novartis (Sandoz), TEVA, Merck, AbbVie (Allergan), Sumitomo Dainippon, Hikma, Aurobindo Pharma and Wockhardt, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Beta-lactam and Beta-lactamase Inhibitors manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:
Global Beta-lactam and Beta-lactamase Inhibitors Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (M Units)
Global Beta-lactam and Beta-lactamase Inhibitors Market Segment Percentages, by Type, 2021 (%)
– Penicillins
– Cephalosporins
– Carbapenems
– Monobactams
– Combinations
Global Beta-lactam and Beta-lactamase Inhibitors Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (M Units)
Global Beta-lactam and Beta-lactamase Inhibitors Market Segment Percentages, by Application, 2021 (%)
– Oral
– Intravenous
Global Beta-lactam and Beta-lactamase Inhibitors Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (M Units)
Global Beta-lactam and Beta-lactamase Inhibitors Market Segment Percentages, By Region and Country, 2021 (%)
– North America
– – US
– – Canada
– – Mexico
– Europe
– – Germany
– – France
– – U.K.
– – Italy
– – Russia
– – Nordic Countries
– – Benelux
– – Rest of Europe
– Asia
– – China
– – Japan
– – South Korea
– – Southeast Asia
– – India
– – Rest of Asia
– South America
– – Brazil
– – Argentina
– – Rest of South America
– Middle East & Africa
– – Turkey
– – Israel
– – Saudi Arabia
– – UAE
– – Rest of Middle East & Africa

Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Beta-lactam and Beta-lactamase Inhibitors revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Beta-lactam and Beta-lactamase Inhibitors revenues share in global market, 2021 (%)
Key companies Beta-lactam and Beta-lactamase Inhibitors sales in global market, 2017-2022 (Estimated), (M Units)
Key companies Beta-lactam and Beta-lactamase Inhibitors sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:
– Pfizer
– Novartis (Sandoz)
– TEVA
– Merck
– AbbVie (Allergan)
– Sumitomo Dainippon
– Hikma
– Aurobindo Pharma
– Wockhardt
– Lupin Limited
– Fresenius Kabi
– B. Braun
– USantibiotics
– Qilu Pharmaceutical
– ACS Dobfar
– Nichi-Iko (Sagent)
– Antibiotice

More information about Discount offers (25% or More)  @ https://www.reportsnreports.com/contacts/discount.aspx?name=5611977

About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.
We provide 24/7 online and offline support to our customers.

E-mail: [email protected]

Phone: +1 888 391 5441

Share This Post

Post Comment